A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression

Trial Profile

A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Infliximab (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Apr 2018.
    • 23 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
    • 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top